Fig. 1
From: PACAP38-induced migraine attacks are independent of CGRP signaling: a randomized controlled trial
Timeline and study design. This double-blind, randomized, parallel-group study included 38 adult participants with migraine without aura. The participants were randomly assigned to receive a single intravenous infusion of either 300-mg eptinezumab or placebo (isotonic saline). During the in-hospital phase, measurements included headache intensity scores, associated symptoms, mean arterial pressure (MABP), heart rate (HR), facial skin blood flow, and the diameter of the frontal branch of the superficial temporal artery.